241 related articles for article (PubMed ID: 7198507)
1. Continued expression of vinca alkaloid resistance by CCRF-CEM cells after treatment with tunicamycin or pronase.
Beck WT; Cirtain MC
Cancer Res; 1982 Jan; 42(1):184-9. PubMed ID: 7198507
[TBL] [Abstract][Full Text] [Related]
2. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
3. Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamil.
Beck WT; Cirtain MC; Look AT; Ashmun RA
Cancer Res; 1986 Feb; 46(2):778-84. PubMed ID: 3455678
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic and molecular characterization of tumors in nude mice derived from a multidrug-resistant human leukemia cell line.
Hill AB; Beck WT; Trent JM
Cancer Res; 1988 Jan; 48(2):393-8. PubMed ID: 2891436
[TBL] [Abstract][Full Text] [Related]
5. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells.
Warren L; Jardillier JC; Ordentlich P
Cancer Res; 1991 Apr; 51(8):1996-2001. PubMed ID: 1672622
[TBL] [Abstract][Full Text] [Related]
6. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes.
Warren L; Jardillier JC; Malarska A; Akeli MG
Cancer Res; 1992 Jun; 52(11):3241-5. PubMed ID: 1591733
[TBL] [Abstract][Full Text] [Related]
7. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells.
Colin M; Madoulet C; Baccard N; Arsac F; Jardillier JC
Anticancer Res; 1994; 14(6A):2383-7. PubMed ID: 7825977
[TBL] [Abstract][Full Text] [Related]
8. Alterations of vinblastine influx in multidrug-resistant lymphoblastic leukaemic CEM cells.
Colin M; Madoulet C; Warren L; Jardillier JC
Anticancer Res; 1996; 16(1):407-12. PubMed ID: 8615645
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.
Beck WT; Cirtain MC; Danks MK; Felsted RL; Safa AR; Wolverton JS; Suttle DP; Trent JM
Cancer Res; 1987 Oct; 47(20):5455-60. PubMed ID: 2888532
[TBL] [Abstract][Full Text] [Related]
10. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
Irimura T; Gonzalez R; Nicolson GL
Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
[TBL] [Abstract][Full Text] [Related]
11. Resistance to tetracycline, a hydrophilic antibiotic, is mediated by P-glycoprotein in human multidrug-resistant cells.
Kavallaris M; Madafiglio J; Norris MD; Haber M
Biochem Biophys Res Commun; 1993 Jan; 190(1):79-85. PubMed ID: 8093660
[TBL] [Abstract][Full Text] [Related]
12. Effect of tunicamycin on sialomucin and natural killer susceptibility of rat mammary tumor ascites cells.
Bharathan S; Moriarty J; Moody CE; Sherblom AP
Cancer Res; 1990 Sep; 50(17):5250-6. PubMed ID: 2386935
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of tunicamycin resistant mutants from Chinese hamster ovary cells.
Sudo T; Onodera K
J Cell Physiol; 1979 Oct; 101(1):149-56. PubMed ID: 541348
[TBL] [Abstract][Full Text] [Related]
14. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
16. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
17. A phosphoglycoprotein associated with taxol resistance in J774.2 cells.
Roy SN; Horwitz SB
Cancer Res; 1985 Aug; 45(8):3856-63. PubMed ID: 2861892
[TBL] [Abstract][Full Text] [Related]
18. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.
Danks MK; Metzger DW; Ashmun RA; Beck WT
Cancer Res; 1985 Jul; 45(7):3220-4. PubMed ID: 3891080
[TBL] [Abstract][Full Text] [Related]
20. Sanguinarine overcomes P-glycoprotein-mediated multidrug-resistance via induction of apoptosis and oncosis in CEM-VLB 1000 cells.
Weerasinghe P; Hallock S; Tang SC; Trump B; Liepins A
Exp Toxicol Pathol; 2006 Aug; 58(1):21-30. PubMed ID: 16735106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
